Untapped diamonds for untamed diabetes: The α-glucosidase inhibitors

Indian Journal of Endocrinology and Metabolism

Volumn 18, Issue 2, 2014, Pages 138-141

  Kalra, Sanjay ^a   Chadha, Manoj ^b   Sharma, S K ^c   Unnikrishnan, A G ^d  

^a India   (India)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

^c Galaxy Specialty Centre   (India)

^d Chellaram Diabetes Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995426667     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.129102     Document Type: Review

References (16)

1. Hanefeld M, Cagatayb M, Petrowitschb T, Neuserb D, Petzinnab D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-Analysis of seven long-Term studies. Eur Heart J 2004;25:10-6.
2. Chiasson JL, Robert GJ, Ramon G, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-94.
3. Standards of Medical Care in Diabetes-2013-ADA Diabetes Care 2013;36:S11-66
4. International Diabetes Federation, Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes-2012. Available from: http://www.idf.org [Last accessed on 2013 Dec 10].
5. AACE Comprehensive Diabetes Management Algorithm. Endocrine Practice 2013;19(2):327-36. Available from: https://www.aace.com/files/aace-Algorithm.pdf [Last Accessed 2013 Dec 10].
6. Sheu WH, Rosman A, Mithal A, Chung N, Lim YT, Deerochanawong C, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendations. Diabetes Res Clin Pract 2011;92:312-21.
7. International Diabetes Federation-Guideline for management of postmeal glucose 2011 Available from: http://www.idf.org [Last accessed on 2013 Dec 10].
8. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A systematic review and mixed-Treatment comparison meta-Analysis. Open Med 2011;5:E35-48.
9. van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, van Weel C.-Glucosidase inhibitors for patients with type 2 diabetes mellitus: Results from a Cochrane systematic review and meta-Analysis. Diabetes Care 2005;28:166-75.
10. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: Data from a 5-year surveillance study. Diabetes Res Clin Pract 2001;53:193-204.
11. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41.
12. Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in Type 2 diabetes. J Assoc Physicians India 2010;58:679-82.
13. Heiner L. Acarbose an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002;22:141-56.
14. Suzuki Y, Sano M, Hayashida K, Ohsawa I, Ohta S, Fukuda K Are the effects of a-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett FEBS Lett 2009;583:2157-9
15. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: Patient considerations. Diabetes Metab Syndr Obes 2012;5:357-67.
16. Zheng MY, Yang JH, Shan CY, Zhou HT, Xu YG, Wang Y, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: A preliminary report. Cardiovasc Diabetol 2013;12:73.